NCT06055608招募中2 期
Advancing Transplantation Outcomes in Children (CTOT-41)
National Institute of Allergy and Infectious Diseases (NIAID)39 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2024年5月22日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 200
- 试验地点
- 39
- 主要终点
- Incidence of de novo Donor Specific Antibody (dnDSA) (central lab) OR decline in estimated glomerular filtration rate (eGFR) >7.5 mL/min/1.73m^2 (central lab)
研究概览
简要总结
This is a pediatric kidney transplant study comparing the safety and efficacy of an immunosuppressive regimen of belatacept and sirolimus to tacrolimus and Mycophenolate Mofetil (MMF). Two hundred participants will be randomized (1:1) to one of two groups within 24 hours following the transplant procedure. The duration of the study from time of transplant to the primary endpoint is 12-24 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 13 Years 至 20 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant and/or parent/guardian must be able to understand and provide informed consent
- •Male or female, 13-20 years of age at time of enrollment
- •Candidate for primary renal allograft from a living or deceased donor
- •EBV IgG seropositive, defined as evidence of acquired immunity shown by the presence of IgG antibodies to viral capsid antigen (VCA) and EBV nuclear antigen (EBNA)
- •EBV VCA IgM seronegative OR EBV VCA IgM seropositive on two occasions at least 3 months apart and an undetectable EBV PCR result within 1 month prior to enrollment
- •If a female participant of childbearing potential, a negative pregnancy test prior to conducting any study procedures
- •If participant has reproductive potential, agrees to use Food and Drug Administration (FDA) approved methods of birth control for the duration of the study
- •Negative test result for latent tuberculosis infection by tuberculosis skin test (purified protein derivative [PPD]) or Tuberculosis (TB) blood test (interferon gamma release assay [IGRA] i.e., QuantiFERON, T- SPOT.TB) within 12 months
- •In the absence of contraindication, vaccinations must be up to date per the Centers for Disease Control and Prevention (CDC) Guidelines and Division of Allergy, Immunology, and Transplantation (DAIT) Guidance for Patients in Transplant Trials
- •Enrollment criteria for donor source and age will be expanded using a stepwise approach determined by safety monitoring. Expansion criteria will include recipients down to age 6 and living donors. Safety data from each step will be reviewed by the study team, DSMB and FDA. If no safety concerns are identified, inclusion criteria will be expanded.
排除标准
- •Inability or unwillingness to comply with study protocol
- •Active infection requiring treatment, or viremia
- •History of malignancy
- •Receipt of any licensed or investigational live attenuated vaccine(s) within 4 weeks of enrollment
- •Prior history of organ transplantation
- •Listed for multi-organ transplant (e.g. heart- kidney, liver-kidney, multivisceral- kidney, lung- kidney)
- •Active systemic autoimmune disease at time of enrollment
- •Idiopathic Focal Segmental Glomerulosclerosis (FSGS), Membranoproliferative Glomerulonephritis (MPGN), C3 glomerulopathy, or atypical Hemolytic Uremic Syndrome (HUS) suspected at risk for recurrence
- •Use of immunosuppressants, biologics (including IVIG), chronic corticosteroids or investigational drug(s) within 8 weeks of enrollment
- •Known bleeding disorder
- •Sustained platelet count < 75,000 cells/microliters within 3 months of enrollment
- •History of inherited hypercoagulability requiring therapy more than aspirin
- •Panel Reactive Antibody (cPRA) greater than 80 percent
- •Clinically significant unrepaired congenital heart disease causing hemodynamic compromise
- •Uncontrolled diagnosed psychiatric disorder or self-reported drug or alcohol abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements
- •Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study
- •Randomization Inclusion Criteria:
- •Individuals who meet all of the following criteria are eligible for randomization.
- •1. If EBV serology to meet enrollment criteria was performed within 8 weeks of receiving IVIG, EBV VCA IgG and EBV EBNA IgG seropositivity, confirmed between enrollment and time of transplant
- •Randomization Exclusion Criteria:
- •Individuals who meet any of these criteria are not eligible for randomization.
- •Sustained WBC <1500 or >20,000 per microliter within 3 months of randomization
- •Sustained liver function tests (AST and/or ALT) > 2x normal within 3 months of randomization
- •Active systemic autoimmune disease at time of transplant
- •Known bleeding disorder
- •Sustained platelet count < 75,000 cells/microliters within 3 months of enrollment
- •Current (within 45 days) or historical anti-HLA antibody to the donor prior to randomization
- •Recent recipient of any licensed or investigational live attenuated vaccine(s) within 4 weeks of randomization
- •Panel Reactive Antibody (cPRA) greater than 80 percent at any point in time
- •If a female participant of childbearing potential, a positive pregnancy test within 48 hours of randomization (all female participants of childbearing potential must complete a pregnancy test within 48 hours of randomization)
- •Treatment with immunosuppressants within 8 weeks of randomization, except in the case of planned transplant standard of care
- •Treatment with biologics (including IVIG) within 8 weeks of randomization
研究组 & 干预措施
(Group 1): Belatacept+Sirolimus group
Experimental
Participants in this group will receive antithymocyte globulin (ATG) + steroid taper + belatacept + (tacrolimus bridge, day 0-14) with conversion to sirolimus (day 30 +/-14 days)
干预措施: Tacrolimus (Group1) (Drug)
(Group 1): Belatacept+Sirolimus group
Experimental
Participants in this group will receive antithymocyte globulin (ATG) + steroid taper + belatacept + (tacrolimus bridge, day 0-14) with conversion to sirolimus (day 30 +/-14 days)
干预措施: Anti-Thymocyte Globulin (ATG) (Drug)
(Group 2): Tacrolimus + Mycophenolate Mofetil (MMF) group
Active Comparator
Participants in this group will receive anti-thymocyte globulin (ATG) + steroid taper + tacrolimus + MMF
干预措施: Anti-Thymocyte Globulin (ATG) (Drug)
(Group 2): Tacrolimus + Mycophenolate Mofetil (MMF) group
Active Comparator
Participants in this group will receive anti-thymocyte globulin (ATG) + steroid taper + tacrolimus + MMF
干预措施: Tacrolimus (Group 2) (Drug)
(Group 2): Tacrolimus + Mycophenolate Mofetil (MMF) group
Active Comparator
Participants in this group will receive anti-thymocyte globulin (ATG) + steroid taper + tacrolimus + MMF
干预措施: Mycophenolate Mofetil (Drug)
(Group 1): Belatacept+Sirolimus group
Experimental
Participants in this group will receive antithymocyte globulin (ATG) + steroid taper + belatacept + (tacrolimus bridge, day 0-14) with conversion to sirolimus (day 30 +/-14 days)
干预措施: Sirolimus (Drug)
(Group 1): Belatacept+Sirolimus group
Experimental
Participants in this group will receive antithymocyte globulin (ATG) + steroid taper + belatacept + (tacrolimus bridge, day 0-14) with conversion to sirolimus (day 30 +/-14 days)
干预措施: Belatacept (Biological)
结局指标
主要结局
Incidence of de novo Donor Specific Antibody (dnDSA) (central lab) OR decline in estimated glomerular filtration rate (eGFR) >7.5 mL/min/1.73m^2 (central lab)
时间窗: At 96 weeks post-transplant
次要结局
- Time to development of clinical biopsy proven allograft rejection (central lab)(Within 96 weeks post-transplant)
- Time to development of the PTLD(Within 96 weeks post-transplant)
- Incidence of clinical biopsy proven allograft rejection (central lab)(Within 96 weeks post-transplant)
- Incidence of subclinical biopsy proven allograft rejection (central lab)(Within 96 weeks post-transplant)
- Time to development of subclinical biopsy proven allograft rejection (central lab)(Within 96 weeks post-transplant)
- Incidence of Post-Transplant Lymphoproliferative Disease (PTLD)(Within 96 weeks post-transplant)
- Incidence of Grade 3 and above opportunistic infections bacterial, viral, fungal, pneumocystis pneumonia, or parasitic infections assessed as a composite(Within 96 weeks post-transplant)
- Time to development of Grade 3 and above opportunistic infections bacterial, viral, fungal, pneumocystis pneumonia, or parasitic infections assessed as a composite(Within 96 weeks post-transplant)
研究者
研究点 (39)
Loading locations...
相似试验
已完成
不适用
CNTRP POSITIVE StudyTransplantAdaptive ImmunityEBVMedication AdherencePTLDNCT02318030The Hospital for Sick Children600
已完成
不适用
Prognosis Study of Renal Transplantation in ChildrenKidney FailureNCT03708094Children's Hospital of Fudan University184
Unknown
1 期
Safety and Tolerance of Immunomodulating Therapy With Donor-specific MSC in Pediatric Living-Donor Liver TransplantationPediatric Liver TransplantationNCT02957552University Hospital Tuebingen7
已完成
1 期
Safety of Immunosuppression Minimization in Children and Adolescents After Kidney TransplantationKidney TransplantationImmunosuppressionKidney Failure, ChronicNCT00768729National Institute of Allergy and Infectious Diseases (NIAID)7
已完成
不适用
Immune Development in Pediatric Transplantation (IMPACT)Chronic Kidney FailureEnd Stage Renal DiseaseNCT00951353National Institute of Allergy and Infectious Diseases (NIAID)125